Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (45)
Complete (4)

Showing 1-10 of 45

Sorted By:

A-Z
Z-A

Previous Next

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Chronic GVHD After Prior Therapy
A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases (ECLIPSE)
compare ASP-1929 PIT in combination with pembrolizumab to pembrolizumab alone or pembrolizumab plus chemotherapy according to physician's choice (control arm) in HNSCC.
A151804: Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies.
ACCRU_ATOS-Z-201: A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2- Breast Cancer
Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen & Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2- Breast Cancer
ALLO-501A-202: A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA3)
ALLO-501A-202 Randomized, Open-Label Study Evaluating Efficacy and Safety Cemacabtagene Ansegedleucel for Large B-Cell Lymphoma (ALPHA3)
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer
Phase III open-label camizestrant compared to standard adjuvant endocrine therapy ER+/HER2- early breast cancer intermediate-high risk disease recurrence
AVS4TL - 0921: Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records of Cancer Patients (Sema4)
Using comprehensive genomic profiling and proteomics to ID underlying genomic drivers of premalignant or malignant conditions in participants in different stages of disease
bb2121-EAP-001: Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
This study is designed to evaluate the safety and efficacy of nonconforming idecabtagene vicleucel (ide-cel) in subjects with multiple myeloma per the approved prescribing information.
CAMBRIA-1: A Phase III Open-Label Randomised Study to Assess Efficacy & Safety of Extended Therapy with Camizestrant (AZD9833, Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in ER+/HER2- Early Breast Cancer & Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence (enrollment paused 11-Apr-2025)
camizestrant vs ET in patients w/ ER+/HER2- early BC w/ risk for disease recurrence who completed treatment & adjuvant ET for 2-5 years. Duration of treatment is 60 months
CPG-01-201: Early Phase Clinical Trial to Evaluate COM701 in PSOC
Goal of trial is to learn if experimental antibody COM701 delays progression of ovarian cancer in Relapsed PSOC. It will also learn about the safety of COM701.

Previous Next